Titanium nanoparticles (TiO2)/graphene oxide nanosheets (GO): an electrochemical sensing platform for the sensitive and simultaneous determination of benzocaine in the presence of antipyrine.

An effective electrochemical sensing platform for the simultaneous determination of benzocaine (BEN) and antipyrine (ANT) based upon titanium dioxide nanoparticle (TiO2)/graphene oxide nanosheet (GO) bulk modified carbon paste electrodes (TiO2-GO/CPE) is reported. The TiO2-GO/CPE electrochemical sensing platform is found to exhibit linear ranges from 1.0 × 10-6 to 1.0 × 10-4 M and 1.2 × 10-8 to 8.0 × 10-5 M for BEN and ANT, respectively. The TiO2-GO/CPE sensor is explored towards the analysis of BEN and ANT in oral fluid (saliva) and pharmaceutical products. The synergy between the graphene oxide nanosheets and titanium dioxide nanoparticles results in a dramatic enhancement in the sensitivity of the sensor through a combination of increased surface area and improved electron transfer kinetics compared to other electrode alternatives. The fabricated TiO2-GO/CPE exhibits high sensitivity and good stability towards the sensing of BEN and ANT and has the potential to be utilised as a clinical assay and QA in pharmaceutical products

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer-3

Ated quantitative analysis scores dichotomized by the median score for the entire cohort of patients, node-negative patients, and node-positive patients.<p><b>Copyright information:</b></p><p>Taken from "Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer"</p><p>http://breast-cancer-research.com/content/10/2/R35</p><p>Breast Cancer Research : BCR 2008;10(2):R35-R35.</p><p>Published online 23 Apr 2008</p><p>PMCID:PMC2397537.</p><p></p

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer-4

S a loading control in a panel of breast cancer cell lines.<p><b>Copyright information:</b></p><p>Taken from "Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer"</p><p>http://breast-cancer-research.com/content/10/2/R35</p><p>Breast Cancer Research : BCR 2008;10(2):R35-R35.</p><p>Published online 23 Apr 2008</p><p>PMCID:PMC2397537.</p><p></p

Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer

Background: The purpose of this study was to evaluate the prognostic and predictive value of p27 expression in patients with early breast cancer. Patients and methods: Quantitative immunofluorescence assays for p27 were done on a tissue microarray that included 823 samples from patients randomized between anthracycline-based chemotherapy and no chemotherapy. Quantification of p27 was done using the AQUA® system (HistoRx, Inc. Branford, CT). Both p27 nuclear expression and the nuclear to cytoplasmic ratio were assessed. Results: Nuclear p27 expression was not predictive for the efficacy of anthracycline-based chemotherapy [adjusted P = 0.18 for disease-free survival (DFS)] nor prognostic [95% confidence interval (CI) 0.99-1.01, P = 0.49]. However, p27 nuclear/cytoplasmic ratio was predictive for the efficacy of adjuvant chemotherapy (adjusted P = 0.016 DFS). The adjusted hazard ratio (HR) for relapse associated with adjuvant chemotherapy was 0.56 (95% CI 0.37-0.84, P = 0.005) and 1.06 (95% CI 0.76-1.47, P = 0.74) for patients with high and low nuclear/cytoplasmic ratio, respectively. p27 N/C ratio was prognostic in patients treated with chemotherapy (HR for relapse or death for a 1 unit increase in p27 N/C ratio was 0.30, 95% CI 0.12-0.77) but not in the untreated arm (HR for relapse or death was 1.27, 95% CI 0.58-2.8). Conclusions: This study did not confirm the role of p27 nuclear expression as a prognostic parameter. However, the p27 nuclear/cytoplasmic ratio was predictive in patients treated with anthracycline-based chemotherapy. © The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer-1

2 and Bcl-2 antanogene-1 (Bag-1). AQUA, automated quantitative analysis.<p><b>Copyright information:</b></p><p>Taken from "Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer"</p><p>http://breast-cancer-research.com/content/10/2/R35</p><p>Breast Cancer Research : BCR 2008;10(2):R35-R35.</p><p>Published online 23 Apr 2008</p><p>PMCID:PMC2397537.</p><p></p